The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previou...

Por Nicola Huxley, Louise Crathorne, Jo Varley-Campbell, Irina Tikhonova, Tristan Snowsill, Simon Briscoe, Jaime Peters, Mary Bond, Mark Napier, Martin Hoyle
Publicado em 2017-06-01

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technolog...

Por Louise Crathorne, Nicola Huxley, Marcela Haasova, Tristan Snowsill, Tracey Jones-Hughes, Martin Hoyle, Simon Briscoe, Helen Coelho, Linda Long, Antonieta Medina-Lara, Ruben Mujica-Mota, Mark Napier, Chris Hyde
Publicado em 2016-02-01

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness...

Por Ruben Mujica-Mota, Jo Varley-Campbell, Irina Tikhonova, Chris Cooper, Ed Griffin, Marcela Haasova, Jaime Peters, Stefano Lucherini, Juan Talens-Bou, Linda Long, David Sherriff, Mark Napier, John Ramage, Martin Hoyle
Publicado em 2018-09-01